Roche’s small molecule, risdiplam (RG7916), is an orally-available compound developed in collaboration with the SMA Foundation and PTC Therapeutics and which is used to increase the amount of SMN protein made by the SMN2 gene.
There are currently 3 trials for risdiplam, which started in December 2016 in SMA Types 1, 2 & 3:
|Study Name||SMA Population||Age|
|FIREFISH||Type 1||Between 1 & 7 months|
|SUNFISH||Type 2 & 3||Between 2 & 25 years|
|JEWELFISH||Type 2 & 3||Between 12 & 60 years and has received nusinersen or participated in trial of other SMN2-targeting therapy|
|RAINBOWFISH||Presymptomatic||Up to 6 weeks|
A lay explanation of the results obtained through Phase 1 can be found here.
Roche has a dedicated website for these SMA trials, where more information can be found.
Clinical trials registers: